Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6058817 | 1.00 | NAMPT (0.43) | NAMPTHDAC1MMP8PTPRBMKNK2 | |
| SCHEMBL16310724 | 0.87 | NAMPT (0.45) | NAMPTHDAC1GRIN2BALDH1A1CYP17A1 | |
| SCHEMBL6058644 | 0.87 | NAMPT (0.45) | NAMPTHDAC1GRIN2BALDH1A1CYP17A1 | |
| SCHEMBL6059160 | 0.84 | PTPRB (0.44) | NAMPTHDAC1MMP8PTPRBMKNK2 | |
| SCHEMBL6059137 | 0.84 | NAMPT (0.41) | NAMPTHDAC1PTPRBMKNK2GRIN2B | |
| SCHEMBL16296368 | 0.83 | NAMPT (0.47) | NAMPTHDAC1GRIN2BALDH1A1CYP17A1 | |
| SCHEMBL5073948 | 0.83 | NAMPT (0.41) | NAMPTHDAC1PTPRBMKNK2GRIN2B | |
| SCHEMBL10087556 | 0.81 | NAMPT (0.49) | NAMPTHDAC1GRIN2BALDH1A1MAPT | |
| SCHEMBL19157033 | 0.81 | NAMPT (0.44) | NAMPTHDAC1GRIN2BALDH1A1CYP17A1 | |
| SCHEMBL6058751 | 0.81 | NAMPT (0.44) | NAMPTHDAC1MMP8MKNK2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834527-B2 | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2017-12-05 | — | — | US | disclosed |
| US-9834527-B2 | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2017-12-05 | — | — | US | disclosed |
| US-9834527-B2 | Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2017-12-05 | — | — | US | disclosed |
| EP-3027611-B1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-3027611-B1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-07-26 | — | — | EP | disclosed |
| EP-3027611-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFI A, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-06-08 | — | — | EP | disclosed |
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| WO-2014198620-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFIA, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014198620-A1 | MACROCYCLIC UREA DERIVATIVES AS INHIBITORS OF TAFIA, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137618-A1 | Macrocyclic Urea Derivatives as Inhibitors of TAFIa, Their Preparation and Their Use as Pharmaceuticals | TFPI, TFPI2, F12 | NAMPT 2411/4885HDAC1 852/4885MMP8 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.